Long

CELG US, Holds Breakout, strong support, good story - good chart

Although figures not that good as expected still very good story behind the company and holding breakout position after earnings miss. (CELG believes Otezla has achieved a market share lead for psoriatic arthritis shortly after its launch in April). Good fancy LT Buy and Hold. Downside limited.

Clause de non-responsabilité